Charlie Adams

Prix à l'honneur

Legal 500 UK 2025

Leading associate

Charlie is a senior counsel in our Cambridge office specialising in the commercialisation of intellectual property in the life sciences and technology sectors.

Charlie specialises in the commercialisation of intellectual property in the life sciences and technology sectors. He works with clients on key strategic transactions throughout their lifecycle. This ranges from advising start-ups on foundational licensing deals and R&D collaborations through to working with established multinational companies on distribution, manufacturing and other commercial arrangements. He also advises on the IP, commercial and regulatory aspects of VC investment and M&A.

With over a decade of experience in the Cambridge ecosystem, Charlie has a particular focus on leveraging his later-stage experience when advising early-stage clients and regularly delivers training to new founders taking part in life sciences incubators and accelerators throughout the UK.

CV

Since 2025 Senior Counsel, Taylor Wessing

2022 - 2025 Senior Associate, Taylor Wessing

2020 - 2022 Associate, Taylor Wessing

Carrière

Since 2025 Senior Counsel, Taylor Wessing

2022 - 2025 Senior Associate, Taylor Wessing

2020 - 2022 Associate, Taylor Wessing

Formation

2014 LPC, BPP Law School

2013 Graduate diploma in law, BPP Law School

2011 BA Philosophy and social anthropology, University of Cambridge

Prix et distinctions

Legal 500 UK 2025

Featured

Legal 500 UK 2022

Legal 500 UK 2022

Actualités et publications récentes

View Charlie's insights

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Advising SENISCA on its partnership with L'Oréal

4 juillet 2025

par Colin McCall et Charlie Adams

Fusions et acquisitions d’entreprises et marchés financiers internationaux

Advising on Draig Therapeutics' US$140 million series A financing

23 juin 2025

par plusieurs auteurs

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Antiverse and Nxera Pharma enter collaboration to design novel GPCR-targeted antibody therapeutics

7 novembre 2024

par Colin McCall et Charlie Adams

Cliquer ici pour en savoir plus